Israeli clinicians keen on using placebos in treating patients

Three out of five Israeli clinicians report using placebos – inactive treatments or drugs – in treating patients, despite the medical profession's official disapproval of their use, say the authors of a BMJ Online First paper this week.

Over two-thirds of respondents to the researchers' survey admitted they told patients they were receiving genuine medication, and 94% felt placebos were generally or occasionally effective.

The study from Jerusalem surveyed hospital doctors, head nurses and family doctors in community clinics. Circumstances for using placebos varied widely, including diagnosing patients as well as prescribing medication. Respondents also reported using placebos for a wide range of conditions, from anxiety and vertigo, to asthma and even angina.

Significantly only one in twenty respondents felt that placebos should be banned on ethical grounds, while most considered using them in certain circumstances. This raises important ethical questions say the authors, given "the deception involved in administering a placebo".

Within the medical profession placebos are officially frowned upon, and some institutions have banned clinicians from using them. However this study suggests their use is frequent and rising, say the authors. Used wisely, placebos may have a genuine role in treating patients, they suggest. The time has come for the profession to acknowledge their use, so that an open debate on their effectiveness, and the ethics of their application, can take place.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder